Related Experiment Video
Updated: May 31, 2026
Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
Published on: March 12, 2018
Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome
Christopher Roser-Jones1, Mark Chan, Emily L Howard
1Department of Medicine, Divisions of Cardiology and Hematology, Duke University Medical Center, Duke University School of Medicine and Duke Clinical Research Institute, Advanced Biomarkers Program, Durham, NC, USA.
Insights
Optimal anticoagulant therapy for acute coronary syndrome remains elusive. Targeting factor IXa, a key protease in thrombin generation, may offer a more effective strategy for managing thrombotic and bleeding risks.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Background:
- Anticoagulant therapy combined with platelet inhibitors is standard for acute coronary syndrome (ACS) and percutaneous coronary interventions (PCI).
- Current strategies lack optimal balance, failing to consistently reduce thrombotic and bleeding events with minimal side effects.
- Individualized anticoagulation control based on patient and clinical needs is still a challenge.
Purpose of the Study:
- To explore the potential of targeting factor IXa as a novel anticoagulant strategy.
- To identify a more effective approach for managing thrombotic and hemorrhagic events in ACS patients.
Main Methods:
- Review of current literature on anticoagulant therapies in ACS and PCI.
- Analysis of coagulation and thrombosis pathways, focusing on the role of factor IXa.
- Exploration of factor IXa as a pharmacologic target for improved anticoagulation.
Main Results:
- Factor IXa plays a critical role in thrombin generation, central to thrombotic disorders.
- Targeting factor IXa presents a promising avenue for pharmacologic inhibition.
- Further research is needed to define optimal strategies for factor IXa inhibition.
Conclusions:
- Factor IXa is a potential target for developing new anticoagulant therapies.
- Inhibition of factor IXa may offer improved control over thrombotic and bleeding risks in ACS.
- Advancements in understanding coagulation pathways can lead to more precise therapeutic interventions.
Abstract:
Anticoagulant therapy, combined with platelet-directed inhibitors, represents a standard-of-care in the management of patients with acute coronary syndrome, particularly those who require percutaneous coronary interventions. While a vast clinical experience, coupled with large clinical trials have collectively provided guidance, an optimal anticoagulant drug and applied strategy, defined as one that reduces thrombotic and hemorrhagic events consistently, with minimal off-target effects and active control of systemic anticoagulation according to patient and clinical-setting specific need, remains at large. An advancing knowledge of coagulation, hemostasis, and thrombosis suggests that factor IXa, a protease that governs thrombin generation in common thrombotic disorders may represent a prime target for pharmacologic inhibition.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:29Venous Thrombosis III: Interprofessional Care